21:09:22 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-10-23 Kvartalsrapport 2024-Q3
2024-07-15 Kvartalsrapport 2024-Q2
2024-05-10 Ordinarie utdelning ALIF B 0.50 SEK
2024-05-08 Årsstämma 2024
2024-04-24 Kvartalsrapport 2024-Q1
2024-02-02 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-07-14 Kvartalsrapport 2023-Q2
2023-05-05 Ordinarie utdelning ALIF B 1.20 SEK
2023-05-04 Årsstämma 2023
2023-04-26 Kvartalsrapport 2023-Q1
2023-02-02 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-07-15 Kvartalsrapport 2022-Q2
2022-05-06 Ordinarie utdelning ALIF B 2.00 SEK
2022-05-05 Årsstämma 2022
2022-04-28 Kvartalsrapport 2022-Q1
2022-02-04 Bokslutskommuniké 2021
2021-10-22 Kvartalsrapport 2021-Q3
2021-07-15 Kvartalsrapport 2021-Q2
2021-05-06 Ordinarie utdelning ALIF B 1.50 SEK
2021-05-05 Årsstämma 2021
2021-04-28 Kvartalsrapport 2021-Q1
2021-02-03 Bokslutskommuniké 2020
2020-11-20 Bonusutdelning ALIF B 0.5
2020-11-19 Extra Bolagsstämma 2020
2020-10-22 Kvartalsrapport 2020-Q3
2020-07-17 Kvartalsrapport 2020-Q2
2020-05-27 Split ALIF B 1:4
2020-05-08 Ordinarie utdelning ALIF B 0.00 SEK
2020-05-07 Årsstämma 2020
2020-04-28 Kvartalsrapport 2020-Q1
2020-02-06 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-07-12 Kvartalsrapport 2019-Q2
2019-05-10 Ordinarie utdelning ALIF B 2.20 SEK
2019-05-09 Kvartalsrapport 2019-Q1
2019-05-09 Årsstämma 2019
2019-02-12 Bokslutskommuniké 2018
2018-12-20 Extra Bolagsstämma 2018
2018-11-07 Kvartalsrapport 2018-Q3
2018-07-13 Kvartalsrapport 2018-Q2
2018-06-01 Ordinarie utdelning ALIF B 2.20 SEK
2018-05-31 Årsstämma 2018
2018-04-27 Kvartalsrapport 2018-Q1
2018-02-13 Bokslutskommuniké 2017
2017-10-26 Kvartalsrapport 2017-Q3
2017-07-17 Kvartalsrapport 2017-Q2
2017-05-30 Ordinarie utdelning ALIF B 1.50 SEK
2017-05-29 Årsstämma 2017
2017-04-28 Kvartalsrapport 2017-Q1
2017-02-16 Bokslutskommuniké 2016
2016-10-27 Kvartalsrapport 2016-Q3
2016-09-02 Ordinarie utdelning ALIF B 0.00 SEK
2016-09-01 Årsstämma 2016
2016-07-15 Kvartalsrapport 2016-Q2

Beskrivning

LandSverige
ListaLarge Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
AddLife är en koncern med verksamhet inom life-science sektorn. Inom koncernen återfinns specialisering främst mot diagnostik, medicinteknik och biomedicinsk forskning. Verksamhet innehas främst i Norden och Baltikum med kunder inom vård och omsorg, samt forskningsinstitut. Addlife bildades under 2015 vid en avknoppning ur Addtech koncernen. Bolaget har sitt huvudkontor i Stockholm.
2019-07-12 08:00:00

"An European AddLife!"
1 APRIL - 30 JUNE 2019 (3 MONTHS)

  • Net sales increased by 36 percent to SEK 844 million (622), of which organic growth amounted to 2 percent and acquired growth amounted to 32 percent.
  • EBITA increased by 8 percent to SEK 68 million (63), corresponding to an EBITA-margin of 8.1 percent (10.1).
  • Profit after tax amounted to SEK 31 million (35).
  • Cash flow from operating activities amounted to SEK 65 million (29).
1 JANUARY - 30 JUNE 2019 (6 MONTHS)
  • Net sales increased by 39 percent to SEK 1,689 million (1,219), of which organic growth amounted to 3 percent and acquired growth amounted to 34 percent.
  • EBITA increased by 15 percent to SEK 138 million (120), corresponding to an EBITA-margin of 8.2 percent (9.9).
  • Profit after tax increased by 8 percent and amounted to SEK 66 million (61).
  • Earnings per share amounted to SEK 2.44 (2.54). For the 12-month period, earnings per share amounted to SEK 5.24 (5.09).
  • Cash flow from operating activities amounted to SEK 164 million (68).
  • During the interim period, the company raised SEK 501 million in a rights issue.
  • The equity ratio amounted to 47 percent (42).
  • Return on working capital (P/WC) amounted to 53 percent (65).
  • During the interim period, the acquisition of Wellspect HealthCare's business in surgery and respiration was completed. The acquisition is expected to contribute about SEK 170 million to annual sales.
Stockholm, 12 July 2019
AddLife AB (publ)

For more information, contact;
Kristina Willgård, CEO, kristina.willgard@add.life,+46 70 510 12 23
Martin Almgren, CFO, martin.almgren@add.life,+46 70 228 15 45
www.add.life
Teleconference
Investors. analysts and the media are invited to a teleconference at which CEO Kristina Willgård and CFO Martin Almgren will present the interim report. The presentation will be given in English and take about 20 minutes. after which there will be an opportunity to ask questions.
The teleconference will be at 10:00 a.m. on 12 July 2019
The presentation will be available via the following link: https://5569958126.globalmeet.com/MartinAlmgren
Please call on: +46 8 22 90 90 code: 113242

AddLife is an independent player in the Life Science industry that offers high-quality products, services and advice to both the private and public sectors, mainly in the Nordic region. AddLife has about 900 employees in some 40 operating subsidiaries. The Group currently has net sales of around SEK 3.0 billion. AddLife shares are listed on Nasdaq Stockholm.
This information is information that AddLife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 12 July 2019 at 08:00 a.m. CET.